IOPIDINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for IOPIDINE (IOPIDINE).
Alpha-2 adrenergic agonist; reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
| Metabolism | Primarily metabolized by aldehyde reductase and aldehyde dehydrogenase to inactive metabolites. |
| Excretion | Renal excretion (% unchanged drug not determined; metabolites excreted renally) |
| Half-life | 0.5-2 hours (terminal) for topical ophthalmic administration; clinical effect may persist longer due to local tissue binding. |
| Protein binding | 10-20% (mainly to albumin) |
| Volume of Distribution | 3-5 L/kg (indicates extensive tissue distribution) |
| Bioavailability | Ophthalmic: 0.5-1% systemic bioavailability (due to nasal mucosal absorption and gastrointestinal absorption after drainage); negligible after topical ocular use. |
| Onset of Action | Ophthalmic: 5-20 minutes for reduction of intraocular pressure. |
| Duration of Action | Ophthalmic: 8-12 hours (maximum effect at 2-4 hours); used for short-term control of intraocular pressure. |
Adults: 1 drop of 0.5% or 1% ophthalmic solution in the affected eye(s) three times daily, beginning 48 hours prior to surgery and continuing on the day of surgery. Alternatively, for intraocular surgery, 1 drop of 1% solution is administered 1 hour before surgery and 1 drop immediately after surgery.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for ophthalmic use; negligible systemic absorption. For systemic use, refer to clonidine dosing adjustments. |
| Liver impairment | No specific adjustment for ophthalmic use; use with caution in severe hepatic impairment due to possible increased systemic effects. |
| Pediatric use | Not recommended for use in children due to lack of safety and efficacy data. |
| Geriatric use | No specific dose adjustment; however, elderly patients may be more sensitive to systemic effects such as bradycardia or hypotension; use with caution. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for IOPIDINE (IOPIDINE).
| Breastfeeding | It is not known if apraclonidine is excreted in human milk. M/P ratio not available. Due to potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue drug, taking into account importance of drug to mother. Systemic absorption is low with ocular use. |
| Teratogenic Risk | Apraclonidine (Iopidine) is a selective alpha-2 adrenergic agonist. Animal studies have not shown teratogenic effects at doses up to 2 mg/kg/day (5-10 times human dose). No adequate human studies in pregnant women. Use only if potential benefit justifies risk to fetus. First trimester: Risk cannot be excluded; second/third trimester: Limited data, but systemic exposure is low with ocular administration. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to clonidine or any component of the formulation","Concurrent use with MAOIs","Severe cardiovascular disease (e.g., sick sinus syndrome, severe bradycardia)"]
| Precautions | ["Use with caution in patients with cardiovascular disease (bradycardia, hypotension)","May cause CNS depression (drowsiness, fatigue), avoid hazardous activities","Risk of ocular allergic reactions (follicular conjunctivitis, lid edema)","May exacerbate dry eye syndrome","Use with caution in patients with hepatic or renal impairment"] |
Loading safety data…
| Fetal Monitoring | No specific fetal monitoring required. Monitor maternal blood pressure and heart rate as systemic effects (bradycardia, hypotension) may occur. In pregnancy, monitor for maternal hypotension and fetal heart rate if systemic effects suspected. |
| Fertility Effects | Animal studies: No impairment of fertility at doses up to 2 mg/kg/day (5-10 times human dose). Human data: No known effects on human fertility. |